Drug candidate could help L-dopa work better for patients with Parkinson's
A startup called Sinopia Biosciences has developed a drug candidate, SB-0110, that aims to enhance the effectiveness of L-dopa for Parkinson's patients while reducing side effects like dyskinesia. Preclinical results published in Science Translational Medicine show promise for this dual-action treatment.
Why it matters
This addresses a significant unmet need for Parkinson's patients who suffer from the long-term limitations of current standard treatments.
edited by Sadie Harley , reviewed by Andrew Zinin
The article reports on medical research and drug development in a neutral, informative manner.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in